These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23332110)

  • 41. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.
    Azizi M; Ménard J
    Circulation; 2004 Jun; 109(21):2492-9. PubMed ID: 15173039
    [No Abstract]   [Full Text] [Related]  

  • 42. Renin-Angiotensin Inhibition in Combating Malignancy: A Review.
    Rosenthal T; Gavras I
    Anticancer Res; 2019 Sep; 39(9):4597-4602. PubMed ID: 31519556
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments.
    Perini MV; Dmello RS; Nero TL; Chand AL
    Pharmacol Ther; 2020 Jul; 211():107527. PubMed ID: 32173557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Are the antagonists of the renin-angiotensin system also anticancer agents?
    Lonati C; Morganti A
    High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):99-102. PubMed ID: 24916368
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential deployment of angiotensin I converting enzyme inhibitors and of angiotensin II type 1 and type 2 receptor blockers in cancer chemotherapy.
    Molteni A; Heffelfinger S; Moulder JE; Uhal B; Castellani WJ
    Anticancer Agents Med Chem; 2006 Sep; 6(5):451-60. PubMed ID: 17017854
    [TBL] [Abstract][Full Text] [Related]  

  • 46. What could be the better choice between ACE inhibitors and AT1R antagonists in coronavirus disease 2019 (COVID-19) patients?
    Froldi G
    J Med Virol; 2020 Nov; 92(11):2302-2303. PubMed ID: 32369211
    [No Abstract]   [Full Text] [Related]  

  • 47. Telmisartan Induces Osteosarcoma Cells Growth Inhibition and Apoptosis Via Suppressing mTOR Pathway.
    Wang C; Wang WB
    Open Life Sci; 2018 Jan; 13():242-249. PubMed ID: 33817089
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potential biomarkers Ang II/AT1R and S1P/S1PR1 predict the prognosis of hepatocellular carcinoma.
    Ji Y; Chen H; Gow W; Ma L; Jin Y; Hui B; Yang Z; Wang Z
    Oncol Lett; 2020 Nov; 20(5):208. PubMed ID: 32963614
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sunitinib combined with angiotensin-2 type-1 receptor antagonists induces more necrosis: a murine xenograft model of renal cell carcinoma.
    Verhoest G; Dolley-Hitze T; Jouan F; Belaud-Rotureau MA; Oger E; Lavenu A; Bensalah K; Arlot-Bonnemains Y; Collet N; Rioux-Leclercq N; Vigneau C
    Biomed Res Int; 2014; 2014():901371. PubMed ID: 24967411
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Angiotensin inhibition and malignancies: a review.
    Rosenthal T; Gavras I
    J Hum Hypertens; 2009 Oct; 23(10):623-35. PubMed ID: 19339998
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients.
    Böger CA; Götz AK; Krüger B; Hösl M; Schmitz G; Riegger GA; Krämer BK
    Eur J Med Res; 2005 Apr; 10(4):161-8. PubMed ID: 15946912
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rationale for combining blockers of the renin-angiotensin system.
    Azizi M; Wuerzner G
    Semin Nephrol; 2007 Sep; 27(5):544-54. PubMed ID: 17868792
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Angiotensin-2 type 1 receptors (AT1R) and cancers].
    Dolley-Hitze T; Verhoest G; Jouan F; Le Pogamp P; Arlot-Bonnemains Y; Oger E; Belaud-Rotureau MA; Rioux-Leclercq N; Vigneau C
    Nephrol Ther; 2013 Apr; 9(2):85-91. PubMed ID: 23332110
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.